ROCK Inhibitors in Corneal Diseases and Glaucoma-A Comprehensive Review of These Emerging Drugs

Area of Science:

• Ophthalmology
• Pharmacology
• Cell Biology

Background:

• Rho kinase (ROCK) inhibitors represent a novel therapeutic class in ophthalmology.
• Their efficacy is supported by in vitro and clinical evidence for glaucoma and corneal conditions.
• Ripasudil and netarsudil are prominent ROCK inhibitors with regulatory approvals for glaucoma treatment.

Purpose of the Study:

• To provide a comprehensive overview of Rho kinase (ROCK) inhibitors in ophthalmology.
• To discuss their application in glaucoma, corneal pathology, and surgical procedures.
• To offer recommendations on patient selection, efficacy, and adverse effects of ROCK inhibitors.

Main Methods:

• Review of existing in vitro and clinical studies on ROCK inhibitors.
• Analysis of therapeutic regimens, including monotherapy and combination therapy.
• Evaluation of ROCK inhibitors as adjuncts in ophthalmic surgeries.

Main Results:

• ROCK inhibitors demonstrate significant efficacy in treating glaucoma and various corneal pathologies.
• Approved agents like ripasudil and netarsudil are effective in lowering intraocular pressure (IOP) and managing corneal edema.
• ROCK inhibitors show promise in accelerating visual recovery and reducing scarring post-surgery.

Conclusions:

• Rho kinase (ROCK) inhibitors are valuable therapeutic agents in ophthalmology.
• Their use extends from medical management of glaucoma to enhancing surgical outcomes.
• Further research and clinical guidelines are essential for optimizing the use of ROCK inhibitors.